Curtailing side effects in chemotherapy: A tale of PKCδ in cisplatin treatment

Oncotarget

Volumn 3, Issue 1, 2012, Pages 107-111

  Pabla, Navjotsingh ^a,b   Dong, Zheng ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Chemotherapy; Cisplatin; Protein kinase C ; Side effect

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN KINASE C DELTA;

ANIMAL; CELL PROTECTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG TOXICITY; GENETICS; HUMAN; KIDNEY DISEASE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTOPROTECTION; DRUG TOXICITY; HUMANS; KIDNEY DISEASES; NEOPLASMS; PROTEIN KINASE C-DELTA; SIGNAL TRANSDUCTION;

EID: 84863189306     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.439     Document Type: Article

References (44)

1. Chabner BA, Roberts TG, Jr.: Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5:65-72.
2. Cao Y, DePinho RA, Ernst M, Vousden K: Cancer research: past, present and future. Nat Rev Cancer 2011;11:749-754.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100:57-70.
4. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
5. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7:475-485.
6. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-837.
7. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63:12-31.
8. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-7279.
9. Jamieson ER, Lippard SJ: Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 1999; 99:2467-2498.
10. Cohen SM, Lippard SJ: Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001; 67:93-130.
11. Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ: Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999; 399:708-712.
12. Siddik ZH: Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res 2002; 112:263-284.
13. Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73:994-1007.
14. Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 2003; 23:460-464.
15. Hodeify R, Megyesi J, Tarcsafalvi A, Safirstein RL, Price PM: Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase. Am J Physiol Renal Physiol 2010; 299:F112-120.
16. Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-842.
17. Cummings BS, Schnellmann RG: Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002; 302:8-17.
18. Pabla N, Murphy RF, Liu K, Dong Z: The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296:F505-511.
19. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB: Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010; 2:2490-2518.
20. Ramesh G, Reeves WB: TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003; 285:F610-618.
21. Ramesh G, Zhang B, Uematsu S, Akira S, Reeves WB: Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am J Physiol Renal Physiol 2007; 293:F325-332.
22. Zhang B, Ramesh G, Norbury CC, Reeves WB: Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007; 72:37-44.
23. Palab N, Huang S, Mi QS, Daniel R, Dong Z: ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008; 83:6572-6583.
24. Parker PJ, Murray-Rust J: PKC at a glance. J Cell Sci 2004; 117:131-132.
25. Kikkawa U, Matsuzaki H, Yamamoto T: Protein kinase C delta (PKC delta): activation mechanisms and functions. J Biochem 2002;132:831-839.
26. Liu WS, Heckman CA: The sevenfold way of PKC regulation. Cell Signal 1998;10:529-542.
27. DeVries-Seimon TA, Ohm AM, Humphries MJ, Reyland ME: Induction of apoptosis is driven by nuclear retention of protein kinase C delta. J Biol Chem 2007; 282:22307-22314.
28. Humphries MJ, Ohm AM, Schaack J, Adwan TS, Reyland ME: Tyrosine phosphorylation regulates nuclear translocation of PKCdelta. Oncogene 2008; 27:3045-3053.
29. Jackson DN, Foster DA: The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival. FASEB J 2004; 18:627-636.
30. Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing RO, Dong Z: Inhibition of PKCdelta reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 2011;121:2709-2722.
31. Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME: Protein kinase C delta is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res 2011; 71: 2087-2097.
32. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 2001; 61: 4301-4305.
33. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle. 2002; 1: 375-382.
34. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest. 2000; 105:533-539.
35. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005; 65: 1918-1924.
36. Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, Darzynkiewicz Z, Blagosklonny MV. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res. 2005; 65: 4401-4407.
37. Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, Blagosklonny MV. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther. 2005; 4: 484-490.
38. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2: 222-233.
39. Darzynkiewicz Z. Novel strategies of protecting non-cancer cells during chemotherapy: are they ready for clinical testing? Oncotarget. 2011; 2: 107-108.
40. van Leeuwen IM, Laín S. Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs. Oncotarget. 2011; 2: 274-276.
41. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A. 2009;106: 3964-3969.
42. Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010; 9: 4474-4476.
43. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010; 1: 639-650.
44. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011; 2: 1352-1367.